KCNJ2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20142742	1.00	1/20
SCHEMBL30367110	1.00	1/20
SCHEMBL1006785	0.90	1/20
SCHEMBL15485012	0.65	1/20
SCHEMBL15484885	0.62	1/20
SCHEMBL1006933	0.56	1/20
SCHEMBL12666973	0.55	1/20
SCHEMBL1006501	0.55	1/20
SCHEMBL1006932	0.55	1/20
SCHEMBL1007218	0.55	1/20
SCHEMBL1005376	0.53	1/20
SCHEMBL1007585	0.52	1/20
SCHEMBL4689831	0.52	1/20
SCHEMBL15485103	0.52	1/20
SCHEMBL1007507	0.52	1/20
SCHEMBL13521117	0.52	1/20
SCHEMBL1008100	0.52	1/20
SCHEMBL1006787	0.51	1/20
SCHEMBL15485041	0.51	1/20
SCHEMBL1007029	0.50	1/20

Clinical trials — most relevant to KCNJ2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease	PHASE4	NOT_YET_RECRUITING
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
CiPA Phase 1 ECG Biomarker Validation Study	PHASE1	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development	nan	COMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNJ2 binder may also engage these)

Protein	Name	Similarity
P63253	—	1.000	P63253 →
P52185	—	1.000	P52185 →
Q9MYY9	—	1.000	Q9MYY9 →
O19182	—	1.000	O19182 →
P35561	—	1.000	P35561 →
P52186	—	1.000	P52186 →
Q64273	—	1.000	Q64273 →
P49656	—	1.000	P49656 →
O18839	—	1.000	O18839 →
F1NHE9	—	1.000	F1NHE9 →
Q4TZY1	—	1.000	Q4TZY1 →
Q9NPI9	—	0.998	Q9NPI9 →
P52187	—	0.995	P52187 →
Q5NVJ6	—	0.994	Q5NVJ6 →
P49658	—	0.994	P49658 →
B7U540	—	0.994	B7U540 →
P52188	—	0.993	P52188 →
P48542	—	0.993	P48542 →
Q9Z307	—	0.993	Q9Z307 →
Q14500	—	0.992	Q14500 →
KCNJ6	G protein-activated inward rectifier potassium channel 2	0.992	landscape →
KCNJ3	G protein-activated inward rectifier potassium channel 1	0.992	landscape →
P63250	—	0.991	P63250 →
P48550	—	0.990	P48550 →
P52191	—	0.990	P52191 →
P63251	—	0.989	P63251 →
P97794	—	0.989	P97794 →
Q90854	—	0.989	Q90854 →
P52190	—	0.989	P52190 →
P52189	—	0.988	P52189 →